The biggest increase in 2-year survival associated with Medicaid expansion was among patients with stage III disease, with a ...

Expanding Medicaid is associated with an increase in receipt of guideline-concordant treatment among nonelderly women ...

Medicaid expansion improved 2-year survival rates and access to guideline-concordant treatment for patients with HR-negative and HER2-positive breast cancer. The study highlights the role of ...

"Breast cancer is far too common, and rates are increasing among ... With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer, Journal of the ...

Trastuzumab duocarmazine (T-Duo) improved progression-free survival ... positive (HER2+) breast cancer. However, ocular toxicity was prevalent, leading to higher discontinuation rates in the ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

For some types of breast cancer, particularly triple-negative breast cancer ... and pertuzumab have drastically improved survival rates for HER2-positive patients. Hormonal therapies remain ...

CIDRAP: Paxlovid Tied To Fewer COVID-19 Hospitalizations, Reduced Risk Of Long COVID A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

“Breast cancer is far too common, and rates are increasing among ... With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer” is now ...